Skip to main content

Factor IX Activity

CPT

85250

Synonyms
  • Antihemophilic Factor B

Test Details

Methodology

The assay consists of the measurement of the clotting time, in the presence of cephalin and activator, in a system in which all the factors are present and in excess except factor IX, which is derived from the sample being tested. Testing coagulation factor activities requires that three dilutions be assayed and analyzed to produce a single result.12,13 The slope of the line created by plotting measured factor concentration against sample dilution is evaluated to discern the presence of inhibitors giving rise to nonparallelism.13 Moreover, samples producing results on initial dilution falling outside the analytic measurement range of the assay are tested at additional dilutions to produce reportable results.13

Result Turnaround Time

2 - 3 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Information

Related Documents

For more information, please view the literature below.

Use

This test is used to evaluate an isolated, prolonged aPTT and to document specific factor IX deficiency.6-9

Special Instructions

If the patient's hematocrit exceeds 55%, the volume of citrate in the collection tube must be adjusted. Refer to Coagulation Collection Procedures for directions.

Limitations

Direct Xa or thrombin inhibitor therapy may cause factitiously low results. Factor IX levels can be diminished in severe liver disease and in vitamin K-deficient patients. This can affect the accuracy of the test in diagnosing hemophilia. Factor IX levels should not be used to determine the carrier status of females. Genetic testing should be used for this purpose. Factor IX inhibitors (both alloantibodies that develop after replacement therapy and autoantibodies that develop spontaneously) can result in falsely low factor IX levels.10,11

Custom Additional Information

Factor IX is a 72 kilodalton vitamin K-dependent glycoprotein proenzyme that is produced by the liver.6 Factor IX's plasma concentration is 3-5 mg/mL and half-life is about 24 hours.6 Factor IX deficiency should be suspected when a patient with excessive bleeding has a normal protime (PT) and an extended activated partial thromboplastin time (aPTT).

Hemophilia B, or Christmas disease, occurs as the result of congenital deficiency of factor IX.6,7 Clinical features of hemophilia B are the same as for hemophilia A, which is caused by factor VIII deficiency (see Factor VIII Activity [086264]). Hemophilia B is less common than hemophilia A, occurring in approximately one of every 30,000 live male births.7 The prevalence is significantly higher in Amish and East Indian populations.8 This condition is transmitted as an X chromosome-linked hereditary disorder.7 The majority of cases occur in men whose mothers are carriers of the genetic defect. A subtype of hemophilia B, hemophilia B Leiden, is characterized by altered developmental expression of factor IX such that plasma factor IX levels may be <1% of normal during childhood, but after puberty may gradually rise to a maximum of 70% of normal.12 Hemophilia B can also occur as the result of spontaneous mutations of the factor IX gene locus.7 Female carriers of hemophilia B may rarely present with excessive bleeding.7 Hemophilia symptoms can also occur in female carriers that have a high degree of lyonization of the factor X alleles.7 Females with Turner syndrome, karyotype XO, can also be symptomatic.7

The severity of hemophilia B can be defined by the level of factor IX activity.7,8 Severe hemophilia is associated with a factor IX level of <1%. Moderate hemophilia B occurs with factor IX levels of 1% to 5% and mild hemophilia has factor IX levels >5%.

Patients with hemophilia B can present with any of a number of bleeding manifestations.6,7 Often, infants with severe hemophilia are first diagnosed during the neonatal period because of excessive bleeding after circumcision or due to cord necrosis.7 Hemophilic infants also frequently suffer from intracranial hemorrhage or scalp hematomas. Spontaneous hemarthroses, a common symptom of hemophilias, typically do not occur until the child starts walking.7,8 Hematomas can often be observed at the sites of intramuscular injections for vaccination or medication. The most common sites of spontaneous bleeding in patients with severe hemophilia are involve the joints and muscles. Recurrent bleeding leads to chronic muscle injury and degeneration of the joint tissue.6,7 Gastrointestinal bleeding can occur in approximately 10% of hemophiliacs.7 Males with mild to moderate hemophilia and female carriers may have an increased bleeding tendency, especially following surgery or trauma.8

Acquired factor IX deficiency can occur as the result of oral anticoagulant therapy or with vitamin K deficiency.6,8 Individuals with advance liver disease can have a generalized decrease in coagulation factors, including factor IX.

Elevation of factor IX, if persistent, has been associated with approximately a twofold increased risk for venous thrombosis.9 The basis for this increased risk is not well understood and the clinical cutoff for risk assessment has yet to be established.9

Hemophilia B patients receiving replacement products can develop inhibitors to factor IX in approximately 3% of cases, due to the production of alloantibodies.6,10 Acquired hemophilia caused by the development of autoantibodies to factor IX can also occur.11 This rare condition can occurs most often in individuals with autoimmune disorders. These patients have bleeding symptoms similar to those seen in congenital hemophilia B.

Specimen Requirements

Specimen

Plasma, frozen

Volume

1 mL

Container

Blue-top (sodium citrate) tube

Collection Instructions

Blood should be collected in a blue-top tube containing 3.2% buffered sodium citrate.1 Evacuated collection tubes must be filled to completion to ensure a proper blood-to-anticoagulant ratio.2,3 The sample should be mixed immediately by gentle inversion at least six times to ensure adequate mixing of the anticoagulant with the blood. A discard tube is not required prior to collection of coagulation samples unless the sample is collected using a winged (butterfly) collection system. With a winged blood collection set a discard tube should be drawn first to account for the dead space of the tubing and prevent under-filling of the evacuated tube.4,5 When noncitrate tubes are collected for other tests, collect sterile and nonadditive (red-top) tubes prior to citrate (blue-top) tubes. Any tube containing an alternative anticoagulant should be collected after the blue-top tube. Gel-barrier tubes and serum tubes with clot initiators should also be collected after the citrate tubes.

Please print and use the Volume Guide for Coagulation Testing to ensure proper draw volume.

Stability Requirements

TemperaturePeriod
Frozen28 days
Freeze/thaw cyclesStable x3

Reference Range

 

 

Factor IX Activity14-16
AgeRange
1 d35–56%
3 d44–97%
1 to 11 m43–121%
1 to 5 y44–127%
6 to 10 y48–145%
11 to 16 y64–216%
>16 y59–143%

 

Storage Instructions

Freeze.

Patient Preparation

Ideally, the patient should not be on anticoagulant therapy. Avoid warfarin (Coumadin®) therapy for two weeks prior to the test and heparin, direct Xa and thrombin inhibitor therapies for about three days prior to testing. Do not draw from an arm with a heparin lock or heparinized catheter.

Causes for Rejection

Severe hemolysis; improper labeling; clotted specimen; specimen diluted with IV fluids; samples thawed in transit; improper sample type; sample out of stability

References

Adcock DM, Gosselin R. Direct oral anticoagulants (DOACs) in the laboratory: 2015 review. Thromb Res. 2015 Jul; 136(1):7-12. 25981138
 
Konkle BA, Fletcher SN. Hemophilia B. Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. In: ® [Internet]. Seattle (WA): University of Washington, Seattle; 1993. 2000 Oct 2 [updated 2025 Aug 7]. PubMed 20301578
 
Miller CH. The Clinical Genetics of Hemophilia B (Factor IX Deficiency). Appl Clin Genet. 2021 Nov 23;14:445-454. PubMed 34848993
 
Müller J, Miesbach W, Prüller F, et al. An Update on Laboratory Diagnostics in Haemophilia A and B. Hamostaseologie. 2022 Aug;42(4):248-260. PubMed 35104901
 
STA® – Deficient IX Instructions For Use (IFU) [package insert]. October 2023.

Footnotes

1. Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol. 1997 Jan;107(1):105-110. 8980376
2. Reneke J, Etzell J, Leslie S, et al. Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. Am J Clin Pathol. 1998 Jun;109(6):754-757. 9620035
3. Clinical Laboratory Standards Institute (CLSI). Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays. 6th ed. CLSI guideline H21. Clinical and Laboratory Standards Institute; 2024.
4. Gottfried EL, Adachi MM. Prothrombin time and activated partial thromboplastin time can be performed on the first tube. Am J Clin Pathol. 1997 Jun;107(6):681-683. 9169665
5. McGlasson DL, More L, Best HA, Norris WL, Doe RH, Ray H. Drawing specimens for coagulation testing: Is a second tube necessary? Clin Lab Sci. 1999 May-Jun;12(3):137-139. 10539100
6. Konkle BA, Fletcher SN. Hemophilia B. Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993. 2000 Oct 2 [updated 2025 Aug 7]. PubMed 20301668
7. Cohen AJ, Kessler CM. Hemophilia A and B. In: Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. Philadelphia, Pa: WB Saunders Co; 2002: 43-56.
8. Triplett DA. Coagulation abnormalities. In: McClatchey KD, ed. Clinical Laboratory Medicine. 2nd ed. Philadelphia, Pa: Lippincott Williams and Wilkins; 2002:1033-1049.
9. Chandler WL, Rogers GM, Sprouse JT, Thompson AR. Elevated hemostatic factor levels as potential risk factors for thrombosis. Arch Pathol Lab Med. 2002 Nov;126(11):1405-1414. 12421150
10. Dimichele D. Inhibitors: Resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002 May;8(3):280-287. 12010424
11. Boggio LN, Green D. Acquired hemophilia. Rev Clin Exp Hematol. 2001 Dec;5(4):389-404. 11844135
12. Castellone DD, Castillo R, Depasse F, et al. Determination of Coagulation Factor Activities Using the One-Stage Clotting Assay. CLSI Guideline H48. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI); 2016.
13. Riley PW, Gallea B, Valcour A. Development and Implementation of a Coagulation Factor Testing Method Utilizing Autoverification in a High-volume Clinical Reference Laboratory Environment. J Pathol Inform. 2017 Jun 19;8:25. PubMed 28706751
14. Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006 Feb;95(2):362-372. PubMed 16493500
15. Summerhayes R, et al. J Thromb Haemost. 2007;5(Supp 2):P-S-397.
16. Labcorp in-house established adult reference interval.
 

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
086298 Factor IX Activity 3187-2 086298 Factor IX Activity % 3187-2
Order Code086298
Order Code NameFactor IX Activity
Order Loinc3187-2
Result Code086298
Result Code NameFactor IX Activity
UofM%
Result LOINC3187-2